



# SZABO SCANDIC

Part of Europa Biosite

## Produktinformation



Forschungsprodukte & Biochemikalien



Zellkultur & Verbrauchsmaterial



Diagnostik & molekulare Diagnostik



Laborgeräte & Service

Weitere Information auf den folgenden Seiten!  
See the following pages for more information!



### Lieferung & Zahlungsart

siehe unsere [Liefer- und Versandbedingungen](#)

### Zuschläge

- Mindermengenzuschlag
- Trockeneiszuschlag
- Gefahrgutzuschlag
- Expressversand

### SZABO-SCANDIC HandelsgmbH

Quellenstraße 110, A-1100 Wien

T. +43(0)1 489 3961-0

F. +43(0)1 489 3961-7

[mail@szabo-scandic.com](mailto:mail@szabo-scandic.com)

[www.szabo-scandic.com](http://www.szabo-scandic.com)

[linkedin.com/company/szaboscandic](https://www.linkedin.com/company/szaboscandic) 

# TECHNICALLY *Speaking*

Place your order with CEDARLANE® or your local distributor.

*Please contact CEDARLANE® for lot specific information.*

## **FITC Anti-Mouse CD45R, B220 (Ly 5) Monoclonal Antibody**

**CL8990F**  
**CL8990F-3**  
**LOT: 8031**

### **DESCRIPTION:**

Cedarlane's anti-mouse CD45R, B220 (Ly 5) monoclonal antibody reacts with a form of the CD45 antigen found on B cells and lytically active subsets of NK cells and non - MHC restricted CTL's <sup>(1,2,3,4)</sup>.

This antibody immunoprecipitates the high molecular weight (220,000 Da) surface molecule of the leukocyte common antigen B220<sup>(1)</sup> on B cells. Applications include flow cytometry and immunoprecipitation. Also reacts with human B cells.

### **PRESENTATION:**

100 µg (CL8990F) or 300 µg (CL8990F-3) FITC conjugated Ig buffered in PBS, 0.02% NaN<sub>3</sub> and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml.

### **STORAGE/STABILITY:**

Store at 4°C. For long term storage, aliquot and freeze unused portion at -20°C in volumes appropriate for single usage. Avoid prolonged exposure to light..

For more information or to place an order please contact...

**CEDARLANE®**  
**LABORATORIES LIMITED**



*toll free: 1-800-268-5058*  
*in North America*

phone: (905) 878-8891 • fax: (905) 878-7800

5516 - 8th Line, R.R.#2, Hornby, Ontario, CANADA L0P 1E0

or visit our website for a list of our international distributors including contact information

website: [www.cedarlanelabs.com](http://www.cedarlanelabs.com) • e-mail: [info@cedarlanelabs.com](mailto:info@cedarlanelabs.com)

**SPECIFICATIONS:**

Clone: RA3-6B2

**Hybridoma Production:**

Immunization: Immunogen: Mouse pre-B tumour cells  
(RAW112)

Donor: Lewis rat spleen

Fusion Partner: S 194/5. XXO. BU-1

Specificity: Mouse CD45R, B220 (Ly 5)

Ig Class: Rat IgG<sub>2a</sub>

Format: FITC conjugated Ig buffered in PBS, 0.02% NaN<sub>3</sub> and EIA grade BSA as a stabilizing protein to bring total protein concentration to 4-5 mg/ml. (Purified from ascitic fluid via Protein G Chromatography).

Antibody Concentration: 0.1 mg/ml

**FLOW CYTOMETRY ANALYSIS:****Method:**

1. Prepare a cell suspension in media A. For cell preparations, deplete the red blood cell population with Lympholyte<sup>®</sup>-M cell separation medium (CL5030).
2. Wash 2 times.
3. Resuspend the cells to a concentration of  $2 \times 10^7$  cells/ml in media A. Add 50  $\mu$ l of this suspension to each tube (each tube will then contain  $1 \times 10^6$  cells, representing 1 test).
4. To each tube 0.2-0.5  $\mu$ g of **CL8990F** or **CL8990F-3** per  $10^6$  cells.
5. Vortex the tubes to ensure thorough mixing of antibody and cells.
6. Incubate the tubes for 30 minutes at 4°C.
7. Wash 2 times at 4°C.
8. Resuspend the cell pellet in 50  $\mu$ l ice cold Media B.
9. Transfer to suitable tubes for flow cytometric analysis containing 15  $\mu$ l of propidium iodide at 0.5 mg/ml in phosphate buffered saline. (This stains dead cells by intercalating DNA).

Media:

- A. Phosphate buffered saline (pH 7.2) + 5% normal serum of host species + sodium azide (100  $\mu$ l of 2M sodium azide in 100 mls).
- B. Phosphate buffered saline (pH 7.2) + 0.5% Bovine serum albumin + sodium azide (100  $\mu$ l of 2M sodium azide in 100 mls).

Results:Tissue Distribution by Flow Cytometry Analysis:

Mouse Strain: C57BL/6

Cell Concentration :  $1 \times 10^6$  cells per tests


Antibody Concentration Used: 0.2  $\mu$ g/ $10^6$  cells,

Human PBL's: 1.0  $\mu$ g/ $10^6$  cells

Isotypic Control: FITC Rat IgG<sub>2a</sub>

Cell SourcePercentage of cells stained above control:

Thymus	0.8%
Spleen	58.4%
Lymph Node	20.9%
Human Peripheral Blood Lymphocytes	24.7%



Cell Source: Spleen

Percentage of cells stained above control: 58.4%

**N.B.** Appropriate control samples should always be included in any labelling studies.

\* For optimal results in various applications, it is recommended that each investigator determine dilutions appropriate for individual use.

**Strain Distribution by Flow Cytometry Analysis:**

Procedure: see page 2

Cell Concentration :  $1 \times 10^6$  cells per tests

Antibody Concentration Used:  $0.5 \mu\text{g}/10^6$  cells

Strains Tested: BALB/c, C3H/He, C57BL/6

Positive: BALB/c, C3H/He, C57BL/6

Negative: none

**REFERENCES:**

- 1) Coffman, B. 1982. Surface antigen expression and immunoglobulin rearrangement during mouse pre-B cell development. *Immunological Rev.* 69:5 - 23.
- 2) Zuhair,, K., Ballas, and Rasmussen, W., 1993. Lymphokine-activated killer cells VII. IL-4 induces an NK1.1 + CD8a+b- TCR  $\alpha\beta$  B220+ lymphokine-activated killer subset.
- 3) Asensi, V., and Kimeno, K., et al. 1989. Treatment of autoimmune MRL/lpr mice with anti-B220 monoclonal antibody reduces the level of anti-DNA antibodies and lymphadenopathies. *Immunology* 68: 204 -208.
- 4) Ballas, A. K., and W. Rasmussen. 1990. Lymphokine-activated killer (LAK) cells. IV. Characterization of murine LAK effector subpopulations, *J. Immunol.* 144:386.
- 5) Whiteland, J.L et al (1995). Immunohistochemical detection of T cell subsets and other leukocytes in paraffin embedded rat and mouse tissues with monoclonal antibodies *J. Histochem. Cytochem.* 43: 313-320.

**FOR RESEARCH USE ONLY**

® is a Registered Trademark of Cedarlane Laboratories Limited.